Bach proposes CAR T payment options for CMS

In a perspectives piece in the New England Journal of Medicine, Peter Bach recommended several different payment options that CMS could employ under its National Coverage Determination (NCD) for CAR Ts, including the use of a single Medicare code for the therapies and coverage with evidence development.

Bach considers various payment scenarios for the two CAR Ts approved in the U.S. to treat diffuse large B cell lymphoma (DLBCL) -- Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) and Yescarta axicabtagene ciloleucel from Gilead Sciences Inc. (NASDAQ:GILD)...